MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • June 25th, 2021 • Elanco Animal Health Inc • Pharmaceutical preparations • Delaware
This Mutual Confidentiality Agreement (this “Agreement”) is entered into as of January 11, 2020 by and between Kindred Biosciences, Inc., a Delaware corporation with its principal place of business at 1555 Bayshore Highway, Suite 200, Burlingame, California 94010 USA (“KindredBio”) and Elanco US Inc., a Delaware corporation with its principal place of business at 2500 Innovation Way, P.O. Box 708, Greenfield IN 46140 (“Elanco”).
Joint Filing AgreementJoint Filing Agreement • June 25th, 2021 • Elanco Animal Health Inc • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Kindred Biosciences, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of the date set forth below.
STRICTLY PRIVATE & CONFIDENTIAL June 11, 2021 Richard Chin, M.D. Chief Executive Officer Kindred Biosciences, Inc. Burlingame, CA 94010 Dear Dr. Chin,Letter Agreement • June 25th, 2021 • Elanco Animal Health Inc • Pharmaceutical preparations
Reference is made to that letter agreement (the “Letter Agreement”), dated as of May 31, 2021, between Kindred Biosciences, Inc. (the “Company”) and Elanco Animal Health Incorporated (“Elanco”). In accordance with Section 7 of the Letter Agreement, the Company and Elanco hereby agree to amend the Letter Agreement as set forth below.
